Novo Nordisk will streamline its Danish administrative functions after releasing plans for two new offices to house senior management and other shared facilities.
The buildings in Bagsværd, Denmark, will cost approximately a billion Danish kroner (€134m) and will be completed by the end of 2013.
Lars Rebien Sørensen, President and CEO, says the offices will give staff the “best conditions for interacting across functional divides and with our colleagues abroad”.
Approximately 14,000 of the company’s 32,000 strong workforce are employed in Denmark – although the exact number of job losses has not been disclosed.
The offices have been inspired by the insulin molecule. They will feature low energy consumption with the aid of sensors, light and ventilation, and will meet the 2015 energy requirements for new builds.
“Although Novo Nordisk is primarily set to grow outside of Denmark in the coming years, we are looking forward to consolidating the administrative functions in Bagsværd, where we have been present since the 1950s,” said Mr Sørensen.